2nd Annual Next Gen Immuno-Oncology Congress

Bangkok, Thailand   July 26-27, 2019

immuno-oncology 2019

Theme: Immuno-Oncology: The Strategic Supernova in Cancer Today

Immuno Oncology 2019, an independently organized by Meetings International event happening in July 26-27, 2019 at Bangkok, Thailand. Our goal is to bring together bright minds to give talks that are idea-focused, and on a wide range of Immuno Oncology related research work, to foster learning, inspiration and wonder and provoke conversations that matter. Meetings International officially welcomes all the participants from all over the world to attend international conference on “Annual Next Gen Immuno-Oncology Congress”.

This conference is mainly accelerating on “Immuno-Oncology: The Strategic Supernova In Cancer Today”. This conference acquires a global platform for Oncologists, Doctors, Researchers, Surgeons, Physicians, Young Researchers, business Delegates to Exchange Ideas and knowledge. Immuno Oncology Conference gathering incorporates Plenary lectures, keynote lectures by famous personalities from around the world in addition to poster presentation, young researcher sessions, symposiums, workshop and Exhibitions.

Session 1. Immuno-Oncology Studies:

The immune system is the body’s natural defence system. It is a collection of organs, cells and special molecules that helps protect you from infections, cancer and other diseases. Immuno-oncology therapies activate our immune system, making it able to recognize cancer cells and destroy them. Breast cancer is one of the major cancer type for which new immune-based cancer treatment are currently in development. Lung cancer surgery carries risks, including bleeding and infection. 

Session 2. Cancer Biomarkers:

Biomarker refers to a substance (or) process that indicates the presence of cancer in the body. There are distinctive biomarkers used for prognosis, diagnosis and epidemiology like, genetic, and imaging biomarkers. In cancer research and medicine, biomarkers are used in three primary ways:

  • To help diagnose conditions, as on account of recognizing beginning period diseases (Diagnostic)
  • To forecast how aggressive a condition is, as in the case of determining a patient's ability to fare in the absence of treatment (Prognostic)
  • To predict how well a patient will react to treatment (Predictive)

Session 3. Immune Checkpoint Inhibitors:

Immunology-based treatment is quickly forming into a viable treatment alternative for an astonishing scope of diseases. We have learned in the course of the most recent decade that capable immunologic effector cells might be obstructed by inhibitory administrative pathways controlled by specific molecules often called "immune checkpoints”. 

Session 4. Cancer Clinical Trials:

To developing new techniques to prevent, detect, and treat cancer. It is through clinical trials that researchers can determine whether new treatments are safe and effective and work better than current treatments. Cancer clinical trials have led to have prompted logical advances that have increased doctor’s understanding of how and why tumour’s develop and grow. This knowledge has helped doctors make progress in preventing cancer, diagnosing cancer, slowing or stopping the development of cancer, and finding cancers that have come back after treatment.

  • Treatment trials
  • Prevention trials
  • Screening trials
  • Quality-of-life/supportive care/palliative care trials
  • Signs & Symptoms
  • Diagnosis of CML
  • Risk factors
  • Treatment & Drugs

Session 5.  Novel Approaches in Cancer & Tumor:

Immunotherapy incorporates several different treatment approaches, each of which has a distinct mechanism of action, and all of which are designed to restore immune function in some manner. This includes: Monoclonal antibodies, Immune checkpoint inhibitors, Therapeutic Cancer vaccines, cytokines, and other non-specific immunotherapies.

  • Revisiting Tumor Metabolism
  • Telomerase: A Target for Cancer Therapeutics
  • Molecular Cancer Therapeutics
  • Metabolomics in Novel Biomarker Discovery

Session 6. Stem Cell Therapy:

Cancer stem cells (CSCs) is the cancer cells found inside tumors  that attributes related with typical undifferentiated organisms called which have the ability to offer  all cell types found in a particular cancer sample CSCs may produce tumors through the immature microorganism procedures of self-restoration and variety into different cell composes. Therefore, for improvement of survival and quality of life of cancer patients, development of specific therapies targeted at CSCs holds hope, particularly for patients with metastatic disease.

Induced pluripotent stem cells: iPSC are derived from skin or blood cells that have been reprogrammed back into an embryonic-like pluripotent state empowers the improvement of a boundless wellspring of a human cell required for helpful purposes.. For example, iPSC can be prodded into becoming beta islet cells to treat diabetes, blood cells to create new blood free of cancer cells for a leukemia patient, or neurons to treat neurological disorders.

Session 7. Future directions in Immuno-Oncology::

Cancer immunotherapy is becoming an appealing and attractive strategy among different therapeutic options over the past years and has showed its power against malignancies. It utilizes the body's immune system to induce anti-tumor response and thus cancer can be defeated  Most recently, cancer immunotherapy field is growing tremendously, such as utilization of cancer vaccinations, chimeric antigen receptor (CAR) T-cell therapy and immune checkpoint blockade therapy. Several clinical trials have investigated their potentials in cancer patients lifesavings.

Session 8. Immune Responses Against Different types of Tumors and Transplants:

Immunoediting induces choice for sure growth cells that loose dominant growth-specific antigens permitting the tumour to progress. Its 3 main phases: elimination, equilibrium and escape. Professionals within the field have hypothesized that ‘apoptotic necrobiosis is poorly immunogenic whereas death necrobiosis is actually immunogenic. Varied strains of human papillomavirus (HPV) are found to play a vital role within the development of cervical cancer. Medicine has applications in varied disciplines of medication, notably within the fields of organ transplantation, oncology, virology, medicine, parasitology, psychiatry, and medical specialty.

  • ABO-Incompatible Transplants
  • Immunologic Mechanisms of Rejection
  • Acute or Chronic Rejection
  • Blood Transfer

Session 9. Cancer Micro and Immuno Environment:

Interactions between malignant and non-transformed cells create the Tumor microenvironment (TME). The non-malignant cells of the TME have a dynamic and often tumor-promoting function at all stages of carcinogenesis .Intercellular communication is driven by a complex and dynamic network of cytokines, chemokine’s, growth factors, and inflammatory and matrix remodeling enzymes against a background of major perturbations to the physical and chemical properties of the tissue.

Session 10.Genomics and Precision Medicine for Immuno Oncology:

Tumors often evade immune demolition by adapting and circumventing immune checkpoints to create resistance. This versatile insusceptibility reversed to stimulate the endogenous immune response. Extensive efforts using Immunotherapeutic approaches are currently being investigated for various cancer types to activate our immune system, making it able to recognize these cancer cells and destroy them. Because of the fast extension of genomic advances Precision Medicine in cancer is prompting therapeutic capabilities. 

Session 11.  Cancer Immunology & Immunotherapy:

Immunotherapy is treatment that uses certain parts of a person’s immune system to fight diseases such as cancer. This can be done in a couple of ways: Own immune system stimulation, Biological therapy or biotherapy. These advances in growth immunotherapy are the aftereffect of long haul interests in essential research on the immune system-research that continues today. Additional research is currently under way to: comprehend why immunotherapy is compelling in a few patients however not in other's who have a similar disease, grow the utilization of immunotherapy to more kinds of tumor, increment the viability of immunotherapy by joining it with different sorts of cancer treatment, for example, directed treatment, chemotherapy, and radiation treatment.

Session 12.  Technological Developments of Immuno oncology:

Kineta Immuno-Oncology is Immuno-Oncology is building up an Innovative innovation concentrated on invulnerable incitement on immune stimulation to turn cold tumors hot. Small molecule drugs that target the RIG-I (retinoic acid-inducible gene I) pathway, an effective pathway for drug discovery. The medication instrument drives tumor resistance through direct tumor cell killing and directly activation of antigen presentation cells. It strengthens tumor particular T cells population basic for finish reaction rate of different immunotherapies, for example, check point inhibitors. Novel new immunotherapies are expected to enhance long time survival in Cancer patients.

Session 13. Adoptive T Cell Therapy (ACT):

Verifiably, there have been three mainstays of tumor treatment: surgery, chemotherapy, and radiotherapy. In recent years, immunotherapy has developed as a conceivable fourth column, focusing on Cancer not by its anatomic area or inclination to isolate, however by the innate components the resistant framework uses to recognize sound and pathologic tissue. Adoptive T cell therapy (ACT) is one stone in this new column, a possibly capable way to deal with cancer treatment that relies on the infusion of tumor-specific T cells.

Session 14. Advances in Cancer Treatment:

 The launch of multiple novel agents, coupled with increasing awareness and focus on cancer prevention, and emphasis on early diagnosis, have contributed to improved outcomes and a reduction in mortality rates for many of the major cancers over the past decade. Since 2011, 68 new drugs have been approved for 22 indications, including immuno-oncology agents that have considerably changed the treatment paradigm in many of the cancers .In particular, the immuno-oncology PD-1 and PD-L1 inhibitors have witnessed a rapid uptake based on their remarkable clinical profile and approval for multiple cancers .

Session 15.Preclinical and Translational Immuno-Oncology:

The recent advancements in immunotherapies, such as immune checkpoint modulators, bispecific antibodies, and adoptive T cell transfer, are shifting the way cancer patients are treated. Rapid development of novel immuno-oncology programs is creating the need for predictive preclinical models and translational strategies to understand combination immunotherapy, study responses and resistance to cancer immunotherapy, and identify novel biomarkers and targets.


Market Analysis:

GlobalData estimates that the total IO market will be worth approximately $14 billion in 2019, rising to $34 billion by 2024 in the 7MM (US, France, Germany, Italy, Spain, UK, and Japan). The main drivers of this growth will come from immune checkpoint inhibitors, which will have sales of approximately $10 billion in 2019, rising to $24 billion by 2024. The highest-selling IO drugs by 2024 will be Opdivo and Keytruda, both PD-1 inhibitors, with sales of approximately $10 billion and $7 billion, respectively. This is because these two drugs will be first-to-market in many indications, leapfrogging competition such as Roche's atezolizumab and AstraZeneca's durvalumab.


Overview of IO approaches, including checkpoint inhibitors, cell therapies, peptide vaccines, oncolytic viruses, bi-specific antibodies and CAR-T therapies. Revenue by indications for major IO products in 2019 and 2024. Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the IO therapeutics market. Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late-stage pipeline drugs. Analysis of the current and future market competition in the global IO therapeutics market. Insightful review of the key industry drivers, restraints and challenges. This include analysis of novel combinations and the role of biomarkers such as PD-L1.

Target Audience

  • Immunology  and Molecular Biology Students, Scientists
  • Immunology and Biochemistry Researchers
  • Immunology, Microbiology Faculty
  • Young Researchers
  • Medical Colleges, Hospitals
  • Physicians/Consultants
  • Geneticist, Bioinformatician
  • Immunology, Cellular Biology Associations and Societies
  • Business Entrepreneurs
  • Training Institutes
  • Manufacturing Medical Devices Companies

  Top Global Hospitals 

  • Assistance Publique Hôpitaux de Paris
  • University Clinic Heidelberg Universittsklinikum Heidelberg
  • Erasmus Medisch Centrum Universitait Medisch Centrum Rotterdam
  • Asklepios Klinikum Bad Abbach
  • Leiden University Medical Center / Leids Universitair Medisch Centrum
  • Centre Hospitalier Universitaire Vaudois Lausanne
  • Hôpitaux Universitaires de Geneve
  • Universitätsklinikum Hamburg Eppendorf
  • Universitätsklinikum und Medizinische Fakultät Tübingen
  • Sahlgrenska University Hospital

  Top Global Immunology Universities

  • Harvard University
  • University of California--San Francisco
  • Stanford University
  • Yale University
  • Johns Hopkins University
  • Washington University in St. Louis
  • Duke University
  • University of Pennsylvania
  • University of Texas Southwestern Medical Center-Dallas

Top Global Companies

  • Actelion
  • Amgen
  • AstraZeneca
  • Bayer
  • BioMarin
  • Bristol-Myers Squibb
  • Johnson & Johnson
  • Merck
  • Novartis
  • Pfizer
  • Regeneron
  • Roche
  • Immuno-Oncology Studies
  • Cancer Biomarkers
  • Immune Checkpoint Inhibitors
  • Cancer Clinical Trials
  • Novel Approaches in Cancer & Tumor
  • Stem Cell Therapy
  • Future directions in Immuno-Oncology
  • Immune Responses Against Different types of Tumors and Transplants
  • Cancer Micro and Immuno Environment
  • Genomics and Precision Medicine for Immuno Oncology
  • Cancer Immunology & Immunotherapy
  • Technological Developments of Immuno oncology
  • Adoptive T Cell Therapy (ACT)
  • Advances in Cancer Treatment
  • Preclinical and Translational Immuno-Oncology